Cite
HARVARD Citation
Pivot, X. et al. (n.d.). 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting. Breast. pp. S68-. [Online].